Profile data is unavailable for this security.
About the company
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. In STGD1, it is developing LBS-008 as once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4 which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009 an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
- Revenue in USD (TTM)0.00
- Net income in USD-31.63m
- Incorporated2018
- Employees20.00
- LocationBelite Bio Inc12750 High Bluff Drive Suite 475SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 246-6240
- Websitehttps://belitebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MannKind Corp | 198.96m | -11.94m | 1.19bn | 414.00 | -- | -- | -- | 5.97 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Pharvaris NV | 0.00 | -108.52m | 1.22bn | 82.00 | -- | 2.86 | -- | -- | -2.71 | -2.71 | 0.00 | 7.90 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.22bn | 264.00 | -- | 4.86 | -- | 6.53 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.22bn | 85.00 | -- | 2.68 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Scholar Rock Holding Corp | 0.00 | -165.79m | 1.22bn | 150.00 | -- | 5.18 | -- | -- | -1.99 | -1.99 | 0.00 | 2.96 | 0.00 | -- | -- | 0.00 | -49.55 | -38.14 | -55.26 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.1817 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.23bn | 197.00 | 42.52 | 6.12 | 6.21 | 2.16 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Prothena Corporation PLC | 91.37m | -147.03m | 1.23bn | 173.00 | -- | 2.19 | -- | 13.48 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Pacira Biosciences Inc | 674.98m | 41.96m | 1.27bn | 711.00 | 40.08 | 1.45 | 10.77 | 1.88 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.29bn | 20.00 | -- | 13.93 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.29bn | 267.00 | -- | -- | -- | 2.92 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.29bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| Spyre Therapeutics Inc | 886.00k | -338.79m | 1.31bn | 30.00 | -- | -- | -- | 1,478.04 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.33bn | 58.00 | 25.42 | 1.85 | 14.69 | 10.11 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| 4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.35bn | 147.00 | -- | 3.69 | -- | 65.12 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.36bn | 55.00 | -- | 2.05 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Belite Bio Inc's reporting currency: US Dollar USD
0.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fubon Asset Management Co., Ltd.as of 31 Dec 2023 | 56.51k | 0.19% |
| Armistice Capital LLCas of 31 Dec 2023 | 36.00k | 0.12% |
| Uni-President Asset Management Corp.as of 31 Dec 2023 | 28.04k | 0.10% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 22.42k | 0.08% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 17.56k | 0.06% |
| Cubist Systematic Strategies LLCas of 31 Dec 2023 | 16.88k | 0.06% |
| Marshall Wace LLPas of 31 Dec 2023 | 16.01k | 0.06% |
| JPMorgan Securities LLC (Investment Management)as of 31 Dec 2023 | 14.27k | 0.05% |
| Point72 Asset Management LPas of 31 Dec 2023 | 7.70k | 0.03% |
| Geode Capital Management LLCas of 31 Dec 2023 | 6.70k | 0.02% |
More ▼
Data from 31 Dec 2023 - 03 May 2024Source: FactSet Research Systems Inc.
